title: [Oral disease modifying therapy of multiple sclerosis: the current view].
abstract: The review includes data on experimental and clinical studies of new oral methods of multiple sclerosis (MS) disease modifying therapy (DMT). The mechanisms of action, results of clinical trials of stages II and III with the data on their clinical and MRI-efficacy, tolerability and safety of fingolimod, dimethylfumarate (BG-12), teriflunomide and laquinimod are included. The risk management plans for possible side-effects of every product and the peculiarities of their use in individually selected MS treatment are discussed.
authors.affiliation: Nevrologicheskoe otdelenie i tsentr rasseiannogo skleroza, Kantongospital' Bazelia, Shveĭtsariia.
authors.forename: L
authors.initials: L
authors.lastname: Kappos
authors.forename: A N
authors.initials: AN
authors.lastname: Boĭko